NCT03001297View on ClinicalTrials.gov

Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 17, 2017

Primary Completion Date

August 10, 2018

Study Completion Date

August 10, 2018

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

Placebo

Participants will receive single dose of placebo matched MEDI5884 injection SC on Day 1

BIOLOGICAL

MEDI5884 Dose 1

Participants will receive single dose MEDI5884 Dose 1 injection SC on Day 1.

BIOLOGICAL

MEDI5884 Dose 2

Participants will receive single dose MEDI5884 Dose 2 injection SC on Day 1

BIOLOGICAL

MEDI5884 Dose 3

Participants will receive single dose MEDI5884 Dose 3 injection SC on Day 1

BIOLOGICAL

MEDI5884 Dose 4

Participants will receive single dose MEDI5884 Dose 4 injection SC on Day 1

Trial Locations (1)

91206

Research Site, Glendale

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY